Bexxar tositumomab radiolabeled anti-CD20 monoclonal antibody regulatory update

CRXA said the FDA's Oncologic Drugs Advisory Committee (ODAC) will not review the company's BLA for Bexxar to treat non-Hodgkin's lymphoma (NHL) at ODAC's February meeting. CRXA said it hopes to have ...